"Dynamic Parametric Imaging"

#11950561

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950562

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950563

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950564

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950565

16 Jan 2025

A desk filled with documents during the testing of the new AILIS machine as part of clinical trials aimed at detecting breast cancer, in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. Using Parametric Dynamic Imaging (PDI) and artificial intelligence, it can distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials are currently conducted in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950566

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950567

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950572

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950573

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950574

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950581

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950585

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950589

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950592

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950596

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.

#11950599

16 Jan 2025

The new AILIS machine tests for breast cancer detection during a clinical trial in Krakow, Poland, on December 30, 2024. AILIS is an innovative approach to breast cancer detection, developed by Michal Matuszewski. It uses Parametric Dynamic Imaging (PDI) and artificial intelligence to distinguish areas of increased activity from normal tissue, enabling the identification of cancerous lesions. Clinical trials currently take place in collaboration with the National Oncology Institute in Krakow. Upon successful results, the technology is expected to enter the Polish market first, followed by expansion into Europe. Poland has the highest breast cancer mortality rate in the EU, with early-stage detection standing at only 41%.

Restricted to Editorial Use Only.
Commercial use is not permitted without prior authorization.
Please contact us for more information.